FRACTYL HEALTH, INC. — Investor Relations & Filings

Fractyl Health, Inc. is a metabolic therapeutics company developing therapies that target the root causes of obesity and type 2 diabetes. The company's approach focuses on interventions in the gut, specifically the duodenum and pancreas, to modify the course of these diseases. Its lead product candidates include two proprietary platforms: Revita, an investigational outpatient endoscopic procedure designed to resurface the duodenal lining, and Rejuva, a gene therapy platform in early development designed to target pancreatic islet cells. Fractyl Health aims to provide long-term, disease-modifying treatments that can potentially reverse metabolic diseases and offer an alternative to chronic drug therapies.